Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Galapagos NV Snapshot | 6 | 1 |
| Galapagos NV Overview | 6 | 1 |
| Key Information | 6 | 1 |
| Key Facts | 6 | 1 |
| Galapagos NV Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| Galapagos NV Pipeline Review | 10 | 7 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| Pipeline Products Combination Treatment Modalities | 12 | 1 |
| Pipeline Products Partnered Products | 13 | 1 |
| Partnered Products/Combination Treatment Modalities | 14 | 1 |
| Pipeline Products Out-Licensed Products | 15 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 16 | 1 |
| Galapagos NV Pipeline Products Glance | 17 | 4 |
| Galapagos NV Clinical Stage Pipeline Products | 17 | 1 |
| Phase II Products/Combination Treatment Modalities | 17 | 1 |
| Phase I Products/Combination Treatment Modalities | 18 | 1 |
| Galapagos NV Early Stage Pipeline Products | 19 | 1 |
| Preclinical Products/Combination Treatment Modalities | 19 | 1 |
| Discovery Products/Combination Treatment Modalities | 20 | 1 |
| Galapagos NV Drug Profiles | 21 | 23 |
| filgotinib | 21 | 1 |
| Product Description | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| R&D Progress | 21 | 3 |
| GLPG-1205 | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 2 |
| GLPG-1690 | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| GLPG-1837 | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 2 |
| DT-200 | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 2 |
| GLPG-1972 | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| GLPG-2222 | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| GLPG-2451 | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| MOR-106 | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 2 |
| GLPG-1492 | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| GLPG-1790 | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| GLPG-1837 + GLPG-2222 + GLPG-2665 | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| GLPG-2534 | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| GLPG-2665 | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 1 |
| GLPG-2737 | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| GLPG-2851 | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| GLPG-2938 | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 1 |
| Galapagos NV Pipeline Analysis | 44 | 4 |
| Galapagos NV Pipeline Products by Target | 44 | 1 |
| Galapagos NV Pipeline Products by Route of Administration | 45 | 1 |
| Galapagos NV Pipeline Products by Molecule Type | 46 | 1 |
| Galapagos NV Pipeline Products by Mechanism of Action | 47 | 1 |
| Galapagos NV Recent Pipeline Updates | 48 | 12 |
| Galapagos NV Dormant Projects | 60 | 1 |
| Galapagos NV Discontinued Pipeline Products | 61 | 1 |
| Discontinued Pipeline Product Profiles | 61 | 1 |
| GLPG-0187 | 61 | 1 |
| GLPG-0259 | 61 | 1 |
| GLPG-1179 | 61 | 1 |
| GLPG-1205 | 61 | 1 |
| GLPG-1332 | 61 | 1 |
| GLPG-1577 | 61 | 1 |
| Galapagos NV Locations And Subsidiaries | 62 | 1 |
| Head Office | 62 | 1 |
| Other Locations &Subsidiaries | 62 | 1 |
| Appendix | 63 | 2 |
| Methodology | 63 | 1 |
| Coverage | 63 | 1 |
| Secondary Research | 63 | 1 |
| Primary Research | 63 | 1 |
| Expert Panel Validation | 63 | 1 |
| Contact Us | 63 | 1 |
| Disclaimer | 64 | 1 |